Why this news will impact the lives of people affected by Alzheimer's disease: The first disease-modifying therapies for ...

Based on the insights collected to date, zaltenibart's clinical profile together with its low treatment burden of only four to six times per year is clearly differentiated from treatment options on ..

Tay-Sachs disease, the more common of the two disorders ... Patients often require intensive hospital care as symptoms worsen, and our current treatment options are severely limited. But now, there's ...

When I was diagnosed with Parkinson’s in August 2019, a doctor told me that Sinemet (Levodopa/Carbidopa), the starter drug of ...

Researchers released new clinical guidelines for treating restless legs syndrome (RLS), emphasizing patient-centered care and ...

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

Clene's cash, cash equivalents and marketable securities totaled $14.6 million as of September 30, 2024, compared to $35.0 million as of December 31, 2023. Clene expects that its resources as of ...

Because of this, for some men, ED may be an early warning sign of increased risk for cardiovascular disease ... There are a number of treatment options for ED. Initially, a provider may advise ...

There are several different forms of dementia, with Alzheimer’s disease being the most prevalent ... There are pros and cons ...

Leidos Holdings Inc. $194.40-6.87-3.41% ...